© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 8, 550-552,
April 17, 2002
© 2002 Oxford University Press
NEWS |
On the Eve of Protein Destruction: Ubiquitin Research Begins To Pay Off
For the last three decades, many cancer researchers have focused on the abnormal production of proteins. An overexpressed oncogene or an underexpressed tumor suppressor gene can start cells on the road to cancer. The mechanisms of this malignant transformation have gradually emerged: alteration of signaling cascades, enhancement of angiogenesis, DNA repair defects, cell cycle dysregulation, and inhibition of apoptosis.
Now, protein destruction is vying with protein synthesis for the spotlight. An increasing number of laboratories are studying how cancer is related to ubiquitination, the tagging of proteins by a chain of tiny proteins called ubiquitins for destruction in the proteasome, the cells protein shredder. The ubiquitin field "has gone nuts" in the last 5 years, said Allan Weissman, M.D., chief of the Regulation of Protein Function Laboratory at the National Cancer Institute. In many cases, it is now clear, malignancy results when cells stop degrading a protein, or degrade